Dmytro Kharkov

Zymeworks secures Canadian approval for HER2 cancer therapy

Zymeworks secures Canadian approval for HER2 cancer therapy
Zymeworks gains approval

Zymeworks has announced that Health Canada has approved its HER2-targeted therapy for the treatment of adults with previously treated, unresectable, or metastatic HER2-positive biliary tract cancer.

This advancement marks a significant milestone for the company's development team and partners, underscoring years of dedicated research and effort in the field of oncology treatment. The approval reflects a growing trend towards innovative therapies in the fight against cancer.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.